archive: SETI Market Timing

SETI Market Timing

jon@gte.net
Sat, 31 Oct 98 11:38:05 EST

October 29, 1998

Market Timing

Table of Contents

1. Market Commentary
2. USDI - a player in the IRIDIUM Satellite project
3. NLAB update
4. Departments

1. MARKET COMMENTARY

As predicted in our last issue the US equity markets have
stabilized and begun to head higher again.

Asian markets have had a nice rebound and some currencies
have begun to strengthen against the US dollar. Hong Kong
continues to show some weakness, but these problems can
probably be traced back to the actions of the Chinese
government in Beijing.

During the last week European markets have also begun to
move higher once again. Against this backdrop and more
importantly to our subscribers, there is a groundswell
of interest and commentary developing in and about the
"small cap" sector of the market. The Russell 2000 small
cap index has moved from a low of 303.87 in the first week
of October/98 to close on October 23/98 at 367.05. This
is an increase of over 17% in 2 weeks.

We believe the market is entering a phase where interest
will begin to increase in this long neglected sector of
the market. There are excellent investment grade and
speculative opportunities in this area, which have long
been overlooked by the institutional money managers with
their fixation on the Dow 30 stocks. The DOW is now
beginning to look, if not a little tired, at least fully
valued. The fund managers are now going to have to go
to work and find new areas in which to deploy their
client's money.

Leverage is a bad word on Wall Street these days and without
leverage these managers are stuck with relatively low returns
in the bond and money markets (under 5% on 30 year US treasury
bills). It is our feeling this will result in more money flowing
into the smaller cap sector of the market - and remember - with
the huge amount of money now in mutual funds and the market in
general, it only takes a relatively small reallocation of assets
by market participants, to have a substantial impact on the
price of these smaller company's shares.

2. US DIGITAL COMMUNICATIONS INC. (USDI)

We are profiling a new company in this issue of MT:
US Digital Communications Inc.

Symbol: USDI Trades: OTC BB

USDI is a proxy for one of the biggest events in the
evolution of wirelesses communications the IRIDIUM
Global Communications System. USDI in conjunction
with its subsidiaries SKYSITE (http://www.skysite.com),
INSAT and PROJECT 77 (http://www.project77.com), is a
supplier of both the Motorola and Kyocera telephones
and pagers and a resellers of air time for the IRIDIUM
network. As such, expect to see their revenues and
profits grow in lock step with the growth of the overall
satellite network.

The IRIDIUM satellite phone system consists of 66 low-level
satellites, which completely cover every point of the planet.
This $5 billion dollar investment allows any point or
individual on earth to access telephone, data transfer
or paging service.

The 19 members of this consortium, which has been
spearheaded by Motorola, include some of the largest
telecom companies in the world, as well as a number of
very large Middle Eastern, Asian and South American
private investment companies. The financial commitment
is very large and IRIDIUM (http://www.iridium.com) will
go into service November 1, 1998. The "start" date for
IRIDIUM service is one of the reasons that we are bringing
this company to your attention now.

As you can see if you look at a chart of the stock
(http://www.bigcharts.com) the USDI's share price peaked
at $7.00 in early July of this year, in what we believe
was anticipation of the original service commencement date
of September 23, 1998. When it became obvious this date
was going to be pushed back to November 1, momentum was
lost by the stock. It then bottomed out on October 8 at
$2.30. In the last week it has moved back to close on Friday
(Oct 23) at $3.93 up 7/8s of a point or 28.5% for the day
on 366,200 shares traded! See the October 23 USDI News
Release at:

http://biz.yahoo.com/prnews/981023/dc_fcc_us__1.html

The IRIDIUM name will be on a lot of peoples "radar"
screens soon as a $100 million public relations, marketing
and advertising program will help launch this service.

This is definitely a "timing" and "momentum" play and
there is no doubt that the very wealthy and smart companies
and individuals that are part of the IRIDIUM consortium are
going to work hard to make this THE wireless network of
the future.

Given the momentum that is building in the stock, USDI
could easily see its old high of $7.00 between now and
shortly after startup of the IRIDIUM service in the next
week. Depending on a stable market and some positive news,
which we fully expect, and given the sophistication of the
underwriters and companies behind the IRIDIUM project, USDI
prices above $10 are quite possible over the next 90 days.

4. NUONCOLOGY LABS UPDATE

NuOncology Labs Inc. (NLAB - OTC BB) continues to make
progress on its business plan and have announced the opening
of their new offices, predictive oncology testing and
research building in Houston TX. (See October 15th News
Release at: http://biz.yahoo.com/n/n/nlab.html). This new
facility is capable of performing testing to the rate of
1000 comprehensive predictive profiles per month.

MT heard NuOncology is planning a road show in Europe
that will include NLAB management starting early in
November. These "show and tell" meetings are intended
to attract additional funding, market sponsorship as
well as institutional and broker interest for NLAB.
We expect soon after this trip there will be further
word on the Arglabin/FTI issue by way of publication
of their research in a recognized medical journal.
In addition there will be more results coming on the
second large sample of patients who have been undergoing
treatment for various types of cancer with Arglabin.

The share price has fallen on relatively small volume and
somewhat tracks the skittish market we have had for the last
2 months. It would not be inconceivable that this market
rebounds right back to the $6.50 range in a day or two of
trading - especially if there is some further news on the
use of Arglabin as a successful cancer therapy.

REMEMBER this is not a theoretical concept NLAB is working
on - people ARE BEING TREATED with ARGLABIN today and their
CANCERS ARE IN REMISSIOIN. This company has the potential
to be a $500 million - $1 Billion cap company and we believe
you will begin to see some recognition of this in the
marketplace BEFORE THE END OF NOVEMBER. For a current
quote on NLAB please go to:

http://quote.yahoo.com/q?s=nlab&d=d1

DEPARTMENTS

A. Stock Quotes
B. How to Unsubscribe to MT
C. Disclaimer

A. STOCK QUOTES

For stock quotes on any company please go to:

http://www.bigchart.com

B. HOW TO UNSUBSCRIBE TO MT

Please note, as per your request you are a subscriber
to MT. If at any time you wish to unsubscribe please
put 'unsubscribe' in the subject of your e-mail and return to:

newsletter@premiumservice.com

MT respects your privacy and will NEVER release your e-mail
address to a third party for any reason.

D. DISCLAIMER:

By being a subscriber you are acknowledging you have read
and fully understand our disclaimer below.

MarketTiming (hereafter called MarketTiming) is an
independent electronic publication devoted to providing
information and factual analysis on selected companies
that in the opinion of MarketTiming have investment
potential. Companies featured by MarketTiming may have
paid MarketTiming or their affiliates the editor or the
editor's affiliates family or agents for the dissemination
of company information through MarketTiming. MarketTiming
and/or its affiliates or principals may have been paid in
cash, stock or stock options to disseminate information
about the companies it has featured. These payments may
have been acquired prior to the dissemination of information
on any particular company featured by MarketTiming and stock
positions held by MarketTiming employees, affiliates or
principals may increase or decrease at any time. Such
compensation received by MarketTiming or any of its employees,
the editor or any affiliates should be viewed by readers as
a potential conflict of interest. The principals of
MarketTiming or its affiliates may have from time to time
had business dealings with, or hold a substantial stock
position in any of the companies featured. Principals,
family or affiliates of MarketTiming may also buy hold or
sell securities (long or short) in the companies mentioned
at any time prior to or after a particular company has been
featured by MarketTiming. Our purpose is to locate and
research equity investments in micro or small capitalization
companies that in our opinion has the potential for long-term
appreciation. Investing in any stock must be considered
risky, however investing in the companies MarketTiming reviews
must be considered to be high risk and use of the information
provided is at the investor's sole risk. Purchase of such
high-risk securities may result in loss of some or all of
the investor's original investment. All statements and
expressions are the opinion of MarketTiming and/or its
principals and affiliates and are not meant to be a
solicitation or recommendation to buy, sell, or hold
securities. MarketTiming is not a registered investment
advisor or broker dealer. The information MarketTiming
basis its reports on are generally provided by the
company being featured or may come from sources and/or
interviews conducted by MarketTiming. While every effort
is made to provide true and meaningful information no
guarantee is made by MarketTiming as to the accuracy
of the information provided. Investors should not rely
solely on the information contained in MarketTiming
reports to make an investment decision. They should
consult a registered broker or financial advisor before
purchasing any stock. Investors should consider the
information provided by MarketTiming a starting point
for doing additional independent research on any of the
featured companies. Companies featured are often at
very early stages of development and can therefore be
subject to business failure, which could result in the
investor losing all his or her investment. Statements
of fact in the MarketTiming reports are made as of the
date stated and are subject to change without notice.
Recipients of MarketTiming reports must assume that
there has been a change in the affairs of companies
profiled, from the date of the report - to the time
it may be seen by them. Recipients should independently
ascertain from their own investment advisors or the
company being profiled the current accuracy of any
statements, which may influence their investment decisions.
Investing in micro-cap securities is highly speculative
and carries an extremely high degree of risk. It is
possible that an investor's investment may be lost
or impaired due to the speculative nature of the
companies profiled by MarketTiming. By subscribing to
MarketTiming all subscribers acknowledge they have read
and fully understand the above disclaimer.

end